Investigational Drug Information for Fevipiprant
✉ Email this page to a colleague
What is the drug development status for Fevipiprant?
Fevipiprant is an investigational drug.
There have been 8 clinical trials for Fevipiprant.
The most recent clinical trial was a Phase 3 trial, which was initiated on December 13th 2018.
The most common disease conditions in clinical trials are Asthma, Lung Diseases, and Respiratory Hypersensitivity. The leading clinical trial sponsors are Novartis Pharmaceuticals and [disabled in preview].
There are sixteen US patents protecting this investigational drug and two hundred and thirty-six international patents.
Summary for Fevipiprant
| US Patents | 16 |
| International Patents | 236 |
| US Patent Applications | 66 |
| WIPO Patent Applications | 50 |
| Japanese Patent Applications | 8 |
| Clinical Trial Progress | Phase 3 (2018-12-13) |
| Vendors | 50 |
Recent Clinical Trials for Fevipiprant
| Title | Sponsor | Phase |
|---|---|---|
| Mechanistic Study of Anti-inflammatory Effects of Fevipiprant in Patients With Eosinophilic Asthma. | Novartis Pharmaceuticals | Phase 2 |
| A Proof-of-mechanism Study of Multiple, Oral Doses of Fevipiprant (QAW039) in COPD Patients With Eosinophilia | Novartis Pharmaceuticals | Phase 2 |
| Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to < 12 Years With Asthma | Novartis Pharmaceuticals | Phase 2 |
Clinical Trial Summary for Fevipiprant
Top disease conditions for Fevipiprant
Top clinical trial sponsors for Fevipiprant
US Patents for Fevipiprant
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| Fevipiprant | ⤷ Sign Up | Controlled release dosage form | TRIASTEK, INC. (Nanjing, CN) | ⤷ Sign Up |
| Fevipiprant | ⤷ Sign Up | Therapeutic compounds and compositions, and methods of use thereof | Genentech, Inc. (South San Francisco, CA) | ⤷ Sign Up |
| Fevipiprant | ⤷ Sign Up | Pyrimidine compound as JAK kinase inhibitor | THERAVANCE BIOPHARMA R&D IP, LLC (South San Francisco, CA) | ⤷ Sign Up |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for Fevipiprant
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| Fevipiprant | Australia | AU2017261372 | 2036-05-05 | ⤷ Sign Up |
| Fevipiprant | Canada | CA3023278 | 2036-05-05 | ⤷ Sign Up |
| Fevipiprant | China | CN107847398 | 2036-05-05 | ⤷ Sign Up |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
